Journal
CURRENT OPINION IN MICROBIOLOGY
Volume 15, Issue 1, Pages 92-99Publisher
CURRENT BIOLOGY LTD
DOI: 10.1016/j.mib.2011.10.012
Keywords
-
Categories
Funding
- National Institute of Allergy and Infectious Diseases (NIAID), Infectious Diseases Branch [AI52474, AI92711, AI52767]
- Region V 'Great Lakes' Regional Center of Excellence in Biodefense and Emerging Infectious Diseases Consortium (NIH) [1-U54-AI-057153]
- American Heart Association [10POST4590023]
Ask authors/readers for more resources
Staphylococcus aureus causes purulent skin and soft tissue infections (SSTIs) that frequently reoccur. Staphylococal SSTIs can lead to invasive disease and sepsis, which are among the most significant causes of infectious disease mortality in both developed and developing countries. Human or animal infections with S. aureus do not elicit protective immunity against staphylococcal diseases. Here we review what is known about the immune evasive strategies of S. aureus that enable the pathogen's escape from protective immune responses. Three secreted products are discussed in detail, staphylococcal protein A (SpA), staphylococcal binder of immunoglobulin (Sbi) and adenosine synthase A (AdsA). By forming a complex with V(H)3-type IgM on the surface of B cells, SpA functions as a superantigen to modulate antibody responses to staphylococcal infection. SpA also captures pathogen-specific antibodies by binding their Fc gamma portion. The latter activity of SpA is shared by Sbi, which also associates with complement factors 3d and factor H to promote the depletion of complement. AdsA synthesizes the immune signaling molecule adenosine, thereby dampening innate and adaptive immune responses during infection. We discuss strategies how the three secreted products of staphylococci may be exploited for the development of vaccines and therapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available